Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. [4] Specifically it is used for NSCLC …

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of …

2020年3月18日 · Identify the indications and contraindications for erlotinib therapy in patients with non-small cell lung cancer and advanced pancreatic cancer. Implement evidence-based …

2024年12月18日 · Erlotinib (brand name: Tarceva) is approved by the FDA for the treatment of: Non-small cell lung cancer (NSCLC) with EGRF protein mutations (exon 19 deletions or exon …

Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with …

2020年2月9日 · Tarceva: 25 mg [contains fd&c yellow #6 (sunset yellow)] Tarceva: 100 mg, 150 mg. Generic: 25 mg, 100 mg, 150 mg. Reversibly inhibits overall epidermal growth factor …

Indicated for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution …

Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. …

2023年4月4日 · Erlotinib (Tarceva) is a type of targeted therapy used to treat pancreatic cancer and non-small cell lung cancer. It is a tyrosine kinase inhibitor that works by blocking the …

TARCEVA® CLASSIFICATION: epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 1. Special pediatric considerations are noted when applicable, otherwise adult …